HC Wainwright Issues Negative Forecast for FENC Earnings

Adherex Technologies Inc. (NASDAQ:FENC) – Research analysts at HC Wainwright cut their Q3 2026 EPS estimates for shares of Adherex Technologies in a note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.12 for the quarter, down from their prior forecast of $0.19. The consensus estimate for Adherex Technologies’ current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Adherex Technologies’ Q4 2026 earnings at $0.16 EPS, Q3 2027 earnings at $0.26 EPS, Q4 2027 earnings at $0.30 EPS and FY2027 earnings at $0.96 EPS.

Several other equities research analysts have also issued reports on FENC. Zacks Research lowered Adherex Technologies from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 25th. Wall Street Zen downgraded Adherex Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adherex Technologies in a research report on Thursday, January 22nd. Piper Sandler initiated coverage on shares of Adherex Technologies in a research note on Friday, January 9th. They issued an “overweight” rating and a $18.00 target price for the company. Finally, B. Riley Financial started coverage on shares of Adherex Technologies in a research report on Thursday, February 12th. They issued a “buy” rating and a $16.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.25.

Adherex Technologies Price Performance

Shares of NASDAQ FENC opened at $5.77 on Tuesday. Adherex Technologies has a one year low of $4.68 and a one year high of $9.92. The business’s 50-day moving average price is $7.80 and its two-hundred day moving average price is $8.05. The company has a market capitalization of $198.26 million, a P/E ratio of -16.97 and a beta of 0.75.

Adherex Technologies (NASDAQ:FENC) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.20). The firm had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.73 million.

Insider Transactions at Adherex Technologies

In other Adherex Technologies news, Director Rosty Raykov sold 10,349 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $7.76, for a total transaction of $80,308.24. Following the transaction, the director owned 98,477 shares in the company, valued at $764,181.52. This trade represents a 9.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 10.98% of the stock is owned by insiders.

Institutional Trading of Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC) during the first quarter, according to its most recent filing with the SEC. The firm bought 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned about 0.05% of Adherex Technologies at the end of the most recent quarter. 55.51% of the stock is currently owned by institutional investors.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.